Business Description
Immunovant Inc
NAICS : 325199
SIC : 2834
ISIN : US45258J1025
Total Employee Number:
315Description
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12529.31 | |||||
Equity-to-Asset | 0.89 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -20 | |||||
3-Year EPS without NRI Growth Rate | -19.4 | |||||
3-Year FCF Growth Rate | -13.4 | |||||
3-Year Book Growth Rate | 14.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 15.39 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74 | |||||
9-Day RSI | 72.99 | |||||
14-Day RSI | 69.9 | |||||
3-1 Month Momentum % | 24.99 | |||||
6-1 Month Momentum % | 20.12 | |||||
12-1 Month Momentum % | 83.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.09 | |||||
Quick Ratio | 9.09 | |||||
Cash Ratio | 8.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.1 | |||||
Shareholder Yield % | -6.83 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -68.8 | |||||
ROA % | -62.73 | |||||
ROIC % | -2869.79 | |||||
3-Year ROIIC % | 16724.68 | |||||
ROC (Joel Greenblatt) % | -79371.76 | |||||
ROCE % | -72.52 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.23 | |||||
Price-to-Tangible-Book | 9.23 | |||||
EV-to-EBIT | -13.18 | |||||
EV-to-Forward-EBIT | -9.85 | |||||
EV-to-EBITDA | -13.19 | |||||
EV-to-Forward-EBITDA | -9.85 | |||||
EV-to-FCF | -17.24 | |||||
| Price-to-Net-Current-Asset-Value | 9.32 | |||||
| Price-to-Net-Cash | 9.87 | |||||
Earnings Yield (Greenblatt) % | -7.59 | |||||
FCF Yield % | -5.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMVT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunovant Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.78 | ||
| Beta | 0.3851 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 1.4 | ||
| Volatility % | 58.4 | ||
| 14-Day RSI | 69.9 | ||
| 14-Day ATR ($) | 1.508234 | ||
| 20-Day SMA ($) | 35.2985 | ||
| 12-1 Month Momentum % | 83.54 | ||
| 52-Week Range ($) | 14.32 - 39.28 | ||
| Shares Outstanding (Mil) | 205.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunovant Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunovant Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-10 08:00 | In 127 days | ||
| Second quarter earnings results for 2027 | 2026-11-10 | In 126 days | ||
| General meeting for 2026 | 2026-08-27 13:30 | In 52 days | ||
| First quarter earnings results for 2026 | 2026-08-11 07:00 | In 36 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-20 08:00 | 26.29 (-0.38%) | ||
| Annual report for 2026 | 2026-05-20 | 26.29 (-0.38%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-20 | 26.29 (-0.38%) | ||
| Third quarter earnings conference call for 2025 | 2026-02-06 08:00 | 24.06 (-3.14%) | ||
| Third quarter earnings results for 2025 | 2026-02-06 | 24.06 (-3.14%) | ||
| Second quarter earnings conference call for 2026 | 2025-11-10 08:00 | 23.35 (-0.55%) |
Show
Entries
Immunovant Inc Frequently Asked Questions
What is Immunovant Inc(IMVT)'s stock price today?
The current price of IMVT is $38.60. The 52 week high of IMVT is $39.28 and 52 week low is $14.32.
When is next earnings date of Immunovant Inc(IMVT)?
The next earnings date of Immunovant Inc(IMVT) is 2026-08-11 Est..
Does Immunovant Inc(IMVT) pay dividends? If so, how much?
Immunovant Inc(IMVT) does not pay dividend.
Guru Commentaries on NAS:IMVT
No articles.
Press Release
Articles on Immunovant Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers